论文部分内容阅读
过去报道应用炎痛喜康(Piroxicam)出现溃疡比其它非甾体抗炎药(NSAID)严重。最近美国FDA随机调查1974～1985年服用炎痛喜康与其它7种NSAIDs出现上消化道出血、穿孔、溃疡的相关性作了系统报告。并调查每万张零售处方用药分析:炎痛喜康占6.52,而痛灭定(Tolmetin)苏灵大(Sulindae)、萘普生(naproxen)、苯氧布洛芬(Fenoprofen)、二氟苯水杨酸(diflunisal)、布洛芬(Ibuprofen)、抗炎酸(moelofenamic)分别是5.9、3.56、3.11、3.01、2.78、1.79、1.23。结论认为炎痛喜康与其它NSAIDs临床应用,上消
It has been reported in the past that the use of Piroxicam appears to be more severe than other non-steroidal anti-inflammatory drugs (NSAIDs). Recently, the United States FDA randomly reported the incidence of upper gastrointestinal bleeding, perforation, and ulcer in seven different NSAIDs from 1974 to 1985 systematically. And investigated the analysis of drug use per 10,000 retail prescriptions: Yulong Xikang accounted for 6.52, while Tolmetin Sulindae, naproxen, fenoprofen, difluorobenzene Diflunisal, ibuprofen, and moelofenamic were 5.9, 3.56, 3.11, 3.01, 2.78, 1.79, 1.23, respectively. Conclusions that yinsenkang and other NSAIDs clinical application, the top